Form 4: Enanta Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, sold shares to cover tax obligations related to a restricted stock unit award.

Summary

• Tara Lynn Kieffer, Chief Product Strategy Officer at Enanta Pharmaceuticals, sold 2,283 shares of common stock on December 6, 2024.
• The sale was executed to cover withholding taxes due from the settlement of a portion of a restricted stock unit award granted on November 23, 2022.
• The shares were sold at a weighted-average price of $8.06, with individual transactions ranging from $7.87 to $8.22.
• This transaction was not a discretionary sale by the reporting person but rather a 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, which is neither positive nor negative for the company's outlook.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

Executive stock sales to cover tax obligations are a common practice and do not necessarily indicate a negative outlook for the company.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a standard practice across publicly traded companies.
• The price range of $7.87 to $8.22 is within the typical fluctuations seen in the stock market.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies.

Stakeholder Impact

• The stock sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Enanta Pharmaceuticals, stock sale, insider trading, tax obligations, restricted stock units, executive compensation